Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis

Abstract

Integrin-beta 1 (ITGB1) is aberrantly overexpressed or downregulated in solid cancers; however, its prognostic value remains controversial. Therefore, we conducted a meta-analysis to explore whether ITGB1 expression is correlated with overall survival (OS) and the clinicopathological characteristics of patients with solid cancers. We systematically searched the PubMed, Embase, and Web of Science databases for eligible studies published up to June 1, 2017. In total, 22 studies involving 3,666 patients were included. A sensitivity analysis was performed to assess the validity and reliability of the pooled OS. Among the 22 studies, 7 focused on lung cancer, 3 focused on colorectal cancer, 6 focused on breast cancer, 3 involved melanoma, and 3 involved pancreatic cancer. The pooled results showed that high ITGB1 expression was significantly associated with worse OS in lung cancer (pooled hazard ratio [HR]=1.78, 95% CI: 1.19–2.65, p<0.05) and breast cancer (pooled HR=1.88, 95% CI: 1.46–2.42, p<0.01). In addition, a significant association was observed between high ITGB1 expression and disease-free survival in breast cancer (pooled HR=1.63, 95% CI: 1.17–2.25, p<0.001) and pancreatic cancer (pooled HR=2.49, 95% CI: 1.35–4.61, p<0.001). However, high ITGB1 expression was not related to OS in colorectal cancer, pancreatic cancer, or melanoma. The pooled HRs used to evaluate the prognostic value of increased ITGB1 expression in lung cancer, breast cancer, and pancreatic cancer were not significantly altered, which indicates that the pooled results were robust. The results of this study indicate that the prognostic value of decreased ITGB1 expression varies among solid cancers.

FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer

“…Finally, we analysed the impact of such ECM modifications on tumour cell integrin activation and more specifically on β1 integrin, as overexpression of β1 is correlated with poorer DFS in PDAC (Sun et al , 2018b), and β1 integrin activation mediates adhesion and invasiveness in PDAC lines (Arao et al , 2000). We report here that tumour cell β1 integrin activation is dramatically decreased upon adhesion to ECM deposited by hCAFs treated with FAK‐I compared to non‐treated hCAFs, while β1 integrin expression is not changed (Figs 6L, EV5K and L).…”

CD29 marks superior cytotoxic human T cells

“…S6A, p=0.000125). ITGB1 is expressed by many cell types, including tumor cells (40). Therefore, we used the CD29 + core signature as defined in Figure 5H.…”

High Expression of UBB, RAC1, and ITGB1 Predicts Worse Prognosis among Nonsmoking Patients with Lung Adenocarcinoma through Bioinformatics Analysis

“…Integrin subunit beta 1 ( ITGB1 ) encodes the beta subunit of integrins, which is a heterodimeric cell surface receptor and participates in the carcinogenesis, migration, and invasion of LUAD [ 34 ]. ITGB1 is abnormally expressed in several cancers, including LUAD and breast cancer [ 35 ]. MicroRNA- (miR-) 134 inhibits the migration and metastasis by targeting ITGB1 in NSCLC [ 36 ].…”